Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Rhea-AI Summary
Zenas BioPharma (Nasdaq: ZBIO) announced inducement option grants on December 15, 2025 to two newly hired employees totaling 300,000 non-qualified stock options. The options have a 10-year term and an exercise price of $32.59, equal to the closing price on the grant date. Vesting is over four years: 25% on the one-year anniversary of each employee's start date, then the remainder in 36 equal monthly installments, subject to continued service. Grants are governed by an Inducement Option Award Agreement and were approved by the Compensation Committee in accordance with Nasdaq Listing Rule 5635(c)(4).
Positive
- None.
Negative
- None.
News Market Reaction – ZBIO
In the Dec 22 session, ZBIO gained 17.10%, reflecting a significant positive market reaction. Argus tracked a peak move of +2.1% during that session. Our momentum scanner triggered 9 alerts that day, indicating moderate trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Dec 15 | Clinical trial update | Positive | -19.7% | Partner’s orelabrutinib met primary endpoint in Phase 2b SLE study. |
| Nov 12 | Earnings and update | Positive | +1.7% | Q3 2025 results, strong MoonStone data and major financing agreements. |
| Nov 11 | Investor conferences | Positive | +8.4% | Announced participation in upcoming healthcare investor conferences. |
| Oct 27 | Clinical trial result | Positive | +33.1% | Phase 2 MoonStone trial met primary endpoint in relapsing MS. |
| Oct 08 | License and financing | Positive | +24.2% | InnoCare license for three autoimmune assets plus sizable private placement. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent news flow has been largely positive (clinical wins, licensing, financing), with four of five events showing price moves aligned with the upbeat tone and one notable negative divergence on strong partner trial data.
Over the last few months, Zenas reported multiple clinical and strategic milestones. On Oct 8, it licensed orelabrutinib and two early autoimmune candidates alongside financing. Positive Phase 2 MoonStone data in MS on Oct 27 and a corporate/financing update on Nov 12 reinforced the development and funding story, while conference participation on Nov 11 coincided with gains. A Dec 15 partner Phase 2b success in SLE, however, saw a sharp negative price reaction, contrasting with the otherwise supportive pattern.
Key Terms
non-qualified stock options financial
Nasdaq Listing Rule 5635(c)(4) regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
WALTHAM, Mass., Dec. 19, 2025 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of transformative therapies for patients living with autoimmune diseases, today announced that on December 15, 2025 (the “Grant Date”), the Compensation Committee of the Company’s Board of Directors granted non-qualified stock options to purchase 300,000 shares of the Company’s common stock to two newly hired employees of the Company as an inducement material to such employees’ entry into employment with the Company, in accordance with Nasdaq Listing Rule 5635(c)(4) (the “Inducement Grant”).
The Inducement Grants have a ten-year term and an exercise price per share of
About Zenas BioPharma, Inc.
Zenas is a clinical-stage global biopharmaceutical company committed to becoming a leader in the development and commercialization of transformative therapies for patients living with autoimmune diseases. Our core business strategy combines our experienced leadership team with a disciplined product candidate acquisition approach to identify, acquire and develop product candidates globally that we believe can provide superior clinical benefits to patients living with autoimmune diseases. Zenas is advancing two late-stage, potential franchise molecules, obexelimab and orelabrutinib. Obexelimab, Zenas’ lead product candidate, is a bifunctional monoclonal antibody designed to bind both CD19 and FcγRIIb, which are broadly present across B cell lineage, to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them. We believe that obexelimab’s unique mechanism of action and self-administered, subcutaneous injection regimen may broadly and effectively address the pathogenic role of B cell lineage in chronic autoimmune disease. Orelabrutinib is a potentially best-in-class, highly selective CNS-penetrant, oral, small molecule BTK inhibitor. Orelabrutinib’s mechanism of action targets pathogenic B cells not only in the periphery but also within the CNS. Additionally, it directly modulates macrophages and microglial cells in the CNS, with the potential to address compartmentalized inflammation and disease progression in MS. Zenas’ earlier stage programs include ZB021, a preclinical, potentially best-in-class, oral, IL-17AA/AF inhibitor, and ZB022, a preclinical, potentially best-in-class, oral, brain-penetrant, TYK2 inhibitor. For more information about Zenas BioPharma, please visit https://zenasbio.com/ and follow us on LinkedIn.
The Zenas BioPharma word mark, logo mark, and the “lightning bolt” design are trademarks of Zenas BioPharma, Inc. or its affiliated companies. All rights reserved.
Investor and Media Contact:
Argot Partners
Zenas@argotpartners.com
